FDA approves GSK and Theravance COPD drug

Share this article:

US regulators approved Anoro Ellipta, an inhaled lung drug treatment for use in COPD. The drug—developed in tandem by Glaxo and Theravance—carries a black box warning for an increased risk of asthma-related death. In September, an advisory panel endorsed the drug 11-2. Analysts forecast annual sales of Anoro Ellipta at $2.65 billion by 2018, according to Thomson Reuters.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions